Affordable Access

deepdyve-link
Publisher Website

An Insight into the Current Perspective and Potential Drug Targets for Visceral Leishmaniasis (VL).

Authors
  • Mansuri, Rani1
  • Singh, Jagbir2
  • Diwan, Anupama1
  • 1 School of Pharmaceutical Sciences, Apeejay Stya University, Sohna-Palwal Road, Sohna, Gurgaon, Haryana 122103, India. , (India)
  • 2 Protein Biochemistry Lab, National Institute of Malaria Research, Dwarka, New Delhi, 110077, India. , (India)
Type
Published Article
Journal
Current drug targets
Publication Date
Jan 01, 2020
Volume
21
Issue
11
Pages
1105–1129
Identifiers
DOI: 10.2174/1389450121666200422083735
PMID: 32321399
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Leishmaniasis is one of the six entities on the list of most important diseases of the World Health Organization/Tropical Disease Research (WHO/TDR). After Malaria, it is one of the most prevalent and lethal parasitic diseases. VL is the fatal form of this disease, especially if left untreated. The drugs that are currently available for the treatment of VL are expensive, toxic, or no longer effective, especially in endemic regions. Currently, no vaccine has been developed to immunize humans against VL. The major problems with the current drugs are the development of resistance and their adverse effects. Therefore, there is a strong urge to research and design drugs that have better efficacies and low toxicities as compared to current chemotherapeutic drugs. Leishmania has various enzymes involved in its metabolic pathways, which are unique to either the same genus or trypanosomatids, making them a very suitable, attractive and novel target sites for drug development. One of the significant pathways unique to trypanosomatids is the thiol metabolism pathway, which is involved in the maintenance of redox homeostasis as well as protection of the parasite in the macrophage from oxidative stress-induced damage. In this review the several pathways, their essential enzymes as well as the proposed changes in the parasites due to drug resistance have been discussed to help to understand the most suitable drug target. The thiol metabolism pathway is discussed in detail, providing evidence of this pathway being the most favorable choice for drug targeting in VL. Copyright© Bentham Science Publishers; For any queries, please email at [email protected]

Report this publication

Statistics

Seen <100 times